Results 41 to 50 of about 1,995 (245)

Live-attenuated tetravalent dengue vaccines: The needs and challenges of post-licensure evaluation of vaccine safety and effectiveness. [PDF]

, 2017
Since December 2015, the first dengue vaccine has been licensed in several Asian and Latin American countries for protection against disease from all four dengue virus serotypes.
Asturias, Edwin J, de Albuquerque Luna, Expedito José, Hombach, Joachim, Longini, Ira, Lopez, Anna Lena, Smith, Peter G, Tissera, Hasitha, Vannice, Kirsten, Wichmann, Ole, Yoon, In-Kyu   +9 more
core   +2 more sources

A Novel, Comprehensive A129 Mouse Model for Investigating Dengue Vaccines and Evaluating Pathogenesis [PDF]

, 2023
In search of a mouse model for use in evaluating dengue vaccines, we assessed A129 mice that lacked IFN-α/β receptors, rendering them susceptible to dengue virus (DENV) infection.
Balingit, Jean Claude, Inoue, Shingo, Kohara, Michinori, Morita, Kouichi, Ngwe, Tun Mya Myat, Nwe, Khine Mya, Pandey, Basu Dev, Takamatsu, Yuki, Tsukiyama-Kohara, Kyoko, Urano, Takeshi   +9 more
core   +1 more source

DISEASE IMPACT AND COST-EFFECTIVENESS OF A NEW DENGUE VACCINE TAK003 IN THAILAND

International Journal of Infectious Diseases, 2023
Intro: Dengue, a vector-borne disease, is a global threat to public health with incidence increased from 0.5 to 5.2 million cases between 2010 and 2019.
J. Shen, E. Kharitonova, S. Biswal, M. Sharma, S. Aballea, A. Tytuła, J. Zawieja, P. Towle, R. Hanley   +8 more
doaj   +1 more source

PP77 Cost-Effectiveness Of The Dengue Vaccine (TAK-003) In Brazil [PDF]

Int J Technol Assess Health Care
IntroductionDengue is an arbovirus that causes an acute febrile illness transmitted by the Aedes aegypti mosquito. The TAK-003 vaccine produced with Vero cells using recombinant DNA technology from the live and attenuated virus was approved by the Brazilian regulatory agency for preventing dengue infection, regardless of previous infection.MethodsA ...
Fernandes, Ricardo, da Costa, Márcia Gisele, Tura, Bernardo, Barros, Bruno, Santos, Marisa   +4 more
europepmc   +2 more sources

The effects of public health measures on severe dengue cases: An optimal control approach [PDF]

, 2023
Dengue fever is the most important viral mosquito-borne disease worldwide, with approximately 3.9 billion people at risk of acquiring dengue infection.
Aguiar, M., Srivastav, A.K., Steindarf, V., Stollenwerk, N.   +3 more
core   +1 more source

Adverse Events and Immunization Errors Following a Mass Immunization Campaignwith TAK-003 in Dourados, Brazil: A Post-Marketing Safety Surveillance Analysis. [PDF]

J Med Virol
ABSTRACT This descriptive observational study based on post‐marketing surveillance data evaluates adverse events following immunization (AEFI) associated with the TAK‐003 (Qdenga®) vaccine. Conducted in Dourados, Brazil, between January and November 2024, the study aimed to assess the frequency, nature, and severity of AEFI to inform ...
Anschau LCK, Bortuluzi AMM, Santos ADS, Santos DS, Rodrigues SS, Machado IR, Kfouri RÁ, Sáfadi MAP, Oliveira RD, Croda J.   +9 more
europepmc   +4 more sources

Immunogenicity and safety of lyophilized and liquid dengue tetravalent vaccine candidate formulations in healthy adults: a randomized, phase 2 clinical trial

Human Vaccines & Immunotherapeutics, 2020
Takeda has developed a live-attenuated dengue tetravalent vaccine candidate (TAK-003) which has been shown to be immunogenic with acceptable reactogenicity in phase 1 trials.
Mark Turner, Athanasia Papadimitriou, Peter Winkle, Nathan Segall, Michael Levin, Matthew Doust, Casey Johnson, Gregg Lucksinger, Carlos Fierro, Paul Pickrell, Marsha Raanan, Vianney Tricou, Astrid Borkowski, Derek Wallace   +13 more
doaj   +1 more source

Transcriptome-wide changes in gene expression, splicing, and lncRNAs in response to a live attenuated dengue virus vaccine

Cell Reports, 2022
Summary: The tetravalent dengue vaccine candidate, TAK-003, induces a functional antibody response, but the titers of antibodies against the four serotypes of the dengue virus (DENV) can vary.
Eun-Young Kim, Yan Che, Hansi J. Dean, Ramon Lorenzo-Redondo, Michael Stewart, Caroline K. Keller, Daniel Whorf, Dawson Mills, Nikita N. Dulin, Tiffany Kim, Megan Votoupal, Miriam Walter, Ana Fernandez-Sesma, Heejin Kim, Steven M. Wolinsky   +14 more
doaj   +1 more source

Current Development and Challenges of Tetravalent Live-Attenuated Dengue Vaccines

Frontiers in Immunology, 2022
Dengue is the most common arboviral disease caused by one of four distinct but closely related dengue viruses (DENV) and places significant economic and public health burdens in the endemic areas.
Jue Hou, Weijian Ye, Jianzhu Chen, Jianzhu Chen   +3 more
doaj   +1 more source

Vaccination against dengue fever for travellers Statement of the Swiss Expert Committee for Travel Medicine, an organ of the Swiss Society for Tropical and Travel Medicine, August 2024 [PDF]

Dengue fever, endemic to most tropical and subtropical countries, is a major cause of illness in travellers, but severe dengue, hospitalisation and death are considered rare in this population.
Antonini, Pietro, de Vallière, Serge, Eperon, Gilles, Fehr, Jan, Haller, Sabine, Hatz, Christoph, Landry, Pierre, Neumayr, Andreas, Niederer-Lohrer, Anita, Schlagenhauf, Patricia, Staehelin, Cornelia, Swiss Expert Committee on Travel Medicine (ECTM), Veit, Olivia   +12 more
core   +5 more sources